If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Lars Bastholt is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
interferon alfa-2b Medicine & Life Sciences
Denmark Medicine & Life Sciences
Guidelines Medicine & Life Sciences
Confidence Intervals Medicine & Life Sciences
Head and Neck Neoplasms Medicine & Life Sciences
Placebos Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1995 2019

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

Bastholt, L., Schmidt, H., Bjerregaard, J. K., Herrstedt, J. & Svane, I. M., Sep 2019, In : European Journal of Cancer. 119, p. 122-131

Research output: Contribution to journalJournal articleResearchpeer-review

Melanoma
Population
Disease-Free Survival
Comorbidity
Multivariate Analysis

Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines

European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC), Sep 2019, In : European journal of cancer (Oxford, England : 1990). 118, p. 10-34

Research output: Contribution to journalJournal articleResearchpeer-review

Guidelines
imiquimod
Neoplasms
Dermatology
Fluorouracil

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

Jansen, Y. J. L., Rozeman, E. A., Mason, R., Goldinger, S. M., Geukes Foppen, M. H., Hoejberg, L., Schmidt, H., Van Thienen, J. V., Haanen, J. B. A. G., Tiainen, L., Svane, I. M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A. M., Long, G. V. & 3 others, Atkinson, V., Blank, C. U. & Neyns, B., 1. Jul 2019, In : Annals of Oncology. 30, 7, p. 1154-1161 mdz110.

Research output: Contribution to journalJournal articleResearchpeer-review

Melanoma
Clinical Trials
Blocking Antibodies
Neoplasms
Cohort Studies

Five-year survival with combined nivolumab and ipilimumab in advanced melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hogg, D., Hill, A., Márquez-Rodas, I., Haanen, J., Guidoboni, M., Maio, M., Schöffski, P., Carlino, M. S. & 11 others, Lebbé, C., McArthur, G., Ascierto, P. A., Daniels, G. A., Long, G. V., Bastholt, L., Rizzo, J. I., Balogh, A., Moshyk, A., Hodi, F. S. & Wolchok, J. D., 17. Oct 2019, In : New England Journal of Medicine. 381, 16, p. 1535-1546

Research output: Contribution to journalJournal articleResearchpeer-review

Melanoma
ipilimumab
Disease-Free Survival
Placebos
Quality of Life

High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort

Bastholt, L., Svane, I. M., Bjerregaard, J. K., Herrstedt, J., Hróbjartsson, A. & Schmidt, H., 1. Jul 2019, In : European Journal of Cancer. 115, p. 61-67

Research output: Contribution to journalJournal articleResearchpeer-review

Interleukin-2
Melanoma
Disease-Free Survival
Databases

Activities 2007 2016

  • 7 Talks and presentations in private or public companies

Continuum of management of stage IV in melanoma - Brain metastases

Lars Bastholt (Lecturer)
Oct 2016

Activity: Talks and presentationsTalks and presentations in private or public companies

Selection of thyroid cancer patients for targeted therapies

Lars Bastholt (Lecturer)
13. Sep 2010

Activity: Talks and presentationsTalks and presentations in private or public companies

Beyond medullary thyroid cancer - targeted therapy for other thyroid cancer

Lars Bastholt (Lecturer)
12. Sep 2010

Activity: Talks and presentationsTalks and presentations in private or public companies

Tyrosine Kinase inhibitors for differentiated Thyroid carcinoma. Trial design - logistics, clinical problems, extrathyroidal side effects.

Lars Bastholt (Lecturer)
9. Sep 2009

Activity: Talks and presentationsTalks and presentations in private or public companies

ATA Guidelines: Treatment of advanced metastatic medullary thyroid carcinomas

Lars Bastholt (Lecturer)
5. Sep 2009

Activity: Talks and presentationsTalks and presentations in private or public companies